The officials from FDA have found that more patients of hepatitis C seem to have cured in fewer times with new drug in comparison to past twenty years. New drug called boceprevir, made by New Jersey-based Merck and Company is projected to be suggested by autonomous panel to the FDA.
Hepatitis C is a main cause of liver transplants and it claims more than twelve thousand lives of US patients a year and the number is expected to triple by 2030 because baby boomers surrender to the condition. The disease is frequently linked to use of illegal injectable drugs like heroin, however, it was also picked up from blood transfusions.
Although hepatitis C damages the liver, but the majority of people with hepatitis C do not even know that they have the virus until years later when liver damage has happened. The symptoms of the disease usually come and go and are mild and vague. Unluckily, by the time symptoms appear, the damage may be very serious.
Chronic hepatitis C can escort to cirrhosis of the liver in many people, a condition conventionally related with alcoholism. The symptoms of the condition include, fluid retention causing swelling of the stomach, legs or whole body, persistent jaundice, fatigue, disturbances in sleeping, itchy skin, loss of appetite and weight loss.
In some cases there are mental disturbances like confusion, lethargy, extreme sleepiness, or hallucinations. Bothe drugs work by blocking the enzyme protease that allows the hepatitis virus to replicate. These are different from conventional medications, which are designed to improve the immune system.
The new pill by Merck and Vertex will be prescribed as part of a cocktail with the two older drugs to lower levels of viral. The present treatment cures only forty percent of people and causes side effects like nausea, fatigue and vomiting. However, boceprevir has been shown to enhance cure rates between sixty and sixty-five when combined with the conventional drugs.
According to FDA, two studies submitted by Merck showed patients had undetectable virus levels six months, cutting the standard treatment time in half. Some late-responding patients may require taking the drugs for eight months to eradicate the virus. The primary side effect with Merck’s drug was anaemia, or weakness and fatigue due to lack of oxygen-carrying red blood cells.